Several systematic reviews and meta-analyses revealed that ACE inhibitors, in addition to angiotensin receptor blockers (ARBs), have been shown to improve endothelial dysfunction by flow-mediated vasodilatation (FMD), a widely-used method for evaluate endothelial function [113,114]. The gene discussed is ACE; the disease is endothelial dysfunction.